Incorporation of remote electrical neuromodulation (REN) into usual care reduced migraineurs’ use of acute migraine medication, potentially decreasing the risk of medication overuse headache (MOH), according to a study published in Frontiers in Neurology.

REN is a novel acute migraine treatment “in which upper arm peripheral nerves (median and musculocutaneous) are stimulated to induce conditioned pain modulation—a descending endogenous analgesic mechanism in which sub-threshold conditioning stimulation inhibits pain in remote body regions,” researchers said.

MOH occurs in migraineurs who frequently use medications like triptans, ergots, barbiturates, or opiates. High-frequency use of these medications may not only increase frequency and intensity of headaches, but it can also lead to adverse events such as gastrointestinal issues, renal toxicities, and medication dependency and withdrawal.

In a randomized, double-blind, sham-controlled study, 296 participants received acute treatment for migraine. This parent study included a run-in phase, in which migraine was treated with usual care, in addition to a double-blind REN treatment phase. Of the 296 participants, 160 migraineurs continued with an 8-week open-label extension (OLE), which incorporated REN into usual care. In total, analyses were performed on 117 study participants with episodic migraine, 57 of whom were in the active group during the double-blind treatment phase and 60 of whom were in the sham group.

Researchers compared medication use patterns during the OLE phase to rates in the run-in phase in a within-subject design. This design included OLE participants who used the REN device for treatment of at least 1 migraine attack. Pain intensity at the 2-hour posttreatment point was reported and compared between the cohorts.

The study yielded the following results:

  • Mean (SD) reported attacks across subjects were 3.44 (1.25) in the run-in phase and 3.21 (2.27) in the OLE phase
  • During the OLE, 89.7% (105/117) of the participants treated their attacks only with REN and avoided medications in all their reported attacks compared with 15.4% (18/117) in the run-in phase (P <.0001)
  • When REN was available for the acute treatment of the attacks, 73.5% (86/117) of the participants achieved a 50% or greater reduction in the number of attacks treated with medication and 42.7% (50/117) achieved 100% reduction in the number of attacks treated with medication
  • In OLE, 57.3% (67/117) of participants achieved pain relief at 2 hours post treatment in at least 50% of their attacks, compared with 58.1% (68/117) in the run-in phase (P = 0.999)

 

Read more here.

Subscribe To Our Weekly Newsletter

Subscribe To Our Weekly Newsletter

Get a weekly digest of our posts straight to your inbox! We promise, no spam ever.

You have Successfully Subscribed!

Pin It on Pinterest

Share This